3037217-73-2
Chemical Structure
EYE1118
- CAS No.: 3037217-73-2
- Formula:C23H25ClN8O3
- Molecular Weight:496.95
InChIKey: JVHDMEHABYYKBY-PBTLCFMXSA-N
SMILES: CC1=C(C(N[C@H]2CCN(C(N(C)C)=O)C2)=O)C(C)=C(/C=C3C(NC4=CC(Cl)=C(N=[N+]=[N-])C=C4\3)=O)N1
Biological Activity: EYE1118 is an orally active, photoactivatable VEGFR2 inhibitor without acute hepatotoxicity. EYE1118 mediates light-enhanced inhibition via azide-functionalized receptor binding, and can utilize light-guided targeting to regulate its biodistribution in vivo. EYE1118 effectively inhibits angiogenesis, endothelial cell migration, VEGF-induced retinal leakage, and the size of choroidal neovascular lesions. EYE1118 has been applied in studies related to age-related macular degeneration, diabetic retinopathy, and choroidal neovascularization[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
EYE1118 | EYE1118 is an orally active, photoactivatable VEGFR2 inhibitor without acute hepatotoxicity. EYE1118 mediates light-enhanced inhibition via azide-functionalized receptor binding, and can utilize light-guided targeting to regulate its biodistribution in vivo. EYE1118 effectively inhibits angiogenesis, endothelial cell migration, VEGF-induced retinal leakage, and the size of choroidal neovascular lesions. EYE1118 has been applied in studies related to age-related macular degeneration, diabetic retinopathy, and choroidal neovascularization. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
